Productivity losses during the year (=365 days) before the day of treatment initiation
| Cohort I (mono DMARD) | Cohort II (combo DMARD) | Cohort III (biological agents (RA <5 years)) | Cohort IV (biological agents (all)) | |
|---|---|---|---|---|
| N | 2796 | 973 | 1600 | 4787 |
| Any disability pension (%) | 10 | 12 | 21 | 43 |
| Any sick leave ≥14 days (%) | 59 | 67 | 67 | 53 |
| Any disability pension or sick leave (%) | 64 | 72 | 78 | 80 |
| Mean days (95% CI) | ||||
| Total days | 78 (74 to 82) | 132 (124 to 140) | 171 (164 to 178) | 190 (186 to 194) |
| Days on disability pension | 25 (21 to 28) | 27 (22 to 32) | 51 (46 to 57) | 111 (107 to 115) |
| Days on sick leave | 54 (50 to 57) | 105 (98 to 113) | 120 (113 to 126) | 79 (76 to 82) |
| Median days (25th–75th percentile) | ||||
| Total days | 26 (0–111) | 93 (0–231) | 156 (13–336) | 183 (30–365) |
| Days on disability pension | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–183) |
| Days on sick leave | 15 (0–75) | 58 (0–186) | 70 (0–220) | 11 (0–129) |
Patients initiating treatment 1999–2007 and registered in the Swedish Rheumatology Quality Register, including the Swedish Biologics Register ARTIS.
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.